00:22:25 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2025-06-25 Årsstämma 2025
2025-03-05 Bokslutskommuniké 2024
2024-11-27 Kvartalsrapport 2024-Q3
2024-09-25 Kvartalsrapport 2024-Q2
2024-06-26 Årsstämma 2024
2024-05-29 Kvartalsrapport 2024-Q1
2024-03-06 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-09-26 Kvartalsrapport 2023-Q2
2023-06-21 Årsstämma 2023
2023-06-21 Kvartalsrapport 2023-Q1
2023-03-30 Ordinarie utdelning SOFTX 0.00 NOK
2023-02-17 Bokslutskommuniké 2022
2022-12-09 Extra Bolagsstämma 2022
2022-10-26 Kvartalsrapport 2022-Q3
2022-08-15 Kvartalsrapport 2022-Q2
2022-04-28 Kvartalsrapport 2022-Q1
2022-04-19 Ordinarie utdelning SOFTX 0.00 NOK
2022-04-17 Årsstämma 2022
2022-02-16 Bokslutskommuniké 2021
2021-12-29 Extra Bolagsstämma 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-09-08 Kvartalsrapport 2021-Q2
2021-04-29 Kvartalsrapport 2021-Q1
2021-04-14 Ordinarie utdelning SOFTX 0.00 NOK
2021-04-13 Årsstämma 2021
2021-02-09 Bokslutskommuniké 2020
2020-12-14 Kvartalsrapport 2020-Q3
2020-09-30 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning SOFTX 0.00 NOK
2020-06-30 Kvartalsrapport 2020-Q1
2020-06-30 Årsstämma 2020
2019-12-20 Extra Bolagsstämma 2019
2019-06-27 Årsstämma 2019
2019-06-03 Ordinarie utdelning SOFTX 0.00 NOK
2018-07-02 Split SOFTX 1:50


ListaEuronext Growth Oslo
SoftOx Solutions är ett norskt medicintekniskt bolag. Bolaget har utvecklat en egenpatenterad lösning baserad på ättiksyra för behandling av kroniska sår hos patienter. Lösningen används för att eliminera infektioner i samband med biofilmer, vilket består av olika kluster av bakterier. En del av läkemedelsutvecklingen sker i samarbete med övriga forskningsinstitut. SoftOx Solutions etablerades under 2012 och har sitt huvudkontor i Oslo, Norge.
2023-06-15 12:42:25
Reference is made to the stock exchange announcement made by the board of
directors of SoftOx Solutions AS (the "Company") on 14th June 2023, noticing the
Company's shareholders of the Annual General Meeting to be held on 21st June
2023 at 10:00 hours (CEST).
As item 8 "Approval of issue of Independent Subscription Rights" on the agenda
did not fulfill the requirements in the Private Limited Companies Act, the board
withdraws the existing item and replaces it with the following:
Due to an error, the extraordinary general meeting held on the 30th of May 2023
issued too few warrants to fulfill its obligations under the loan agreement
described in the notice published 23rd of May 2023. As a result, the board
proposes that the general meeting resolved to issue the remaining 800,000
warrants necessary to ensure allocation in accordance with the mentioned loan
The Board thus proposes that the Company's general meeting passes the following
(i) The Company shall issue 799 995 warrants in accordance with the provisions
of the Private Limited Companies Act
section 11-12.
(ii) Each warrant shall give the holder the right to subscribe for one new share
in the Company at a subscription price of NOK 8 per new share. The subscription
amount for shares issued as a result of exercise of warrants within 31 January
2024, shall be settled by way of conversion of debt into new shares.
(iii) The warrants will be granted free of charge and shall not be tradable.
(iv) The warrants are to be subscribed by the persons listed in appendix 1 to
the minutes from the general meeting. The pre-emptive rights of the existing
shareholders under section 11-13 (1) cf. section 10-4 of the Private Limited
Companies Act are set aside.
(v) Subscription of the warrants shall be made no later than 1 July 2023 on a
separate subscription form.
(vi) The warrants may be exercised by written notice to the Company as follows:
a. 228,570 warrants with an exercise price of NOK 8 per share shall be exercised
within 31st of January 2024.
b. 571,425 warrants, with a minimum of 100,000 warrants or wholly if holders
hold a lesser number of warrants, at any date prior to 29th of May 2028.

After expiry of the relevant exercise periods, the relevant warrants will lapse
with no compensation to the holder.

(vii) Shares to be issued as a result of the exercise of warrants shall carry
rights to dividends from the date on which the relevant capital increase is
registered with the Register of Business Enterprises.
(viii) In the event of any split or consolidation of the Company's shares, the
warrants shall be amended based on the same principles that are applied for the
split or consolidation. No other corporate events shall affect the warrants. The
warrants shall not carry any special rights in the event of a liquidation or
transformation of the Company.